Pharming Group N.V. (PHAR)

Market Cap	1.14B +91.7%
Revenue (ttm)	362.27M +26.8%
Net Income	382,000
EPS	0.00
Shares Out	502.26M
PE Ratio	2,977.33
Forward PE	36.53
Dividend	n/a
Ex-Dividend Date	n/a

Volume	11,198
Open	16.42
Previous Close	16.47
Day's Range	16.13 - 16.57
52-Week Range	7.50 - 21.34
Beta	0.23
Analysts	Strong Buy
Price Target	38.00 (+132.27%)
Earnings Date	Mar 12, 2026

About PHAR

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company’s lead product is RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3Kẟ inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also dev...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1988
• Employees: 404
• Stock Exchange: NASDAQ
• Ticker Symbol: PHAR
• Website: https://www.pharming.com

Financial Performance

In 2024, Pharming Group's revenue was $297.20 million, an increase of 21.15% compared to the previous year's $245.32 million. Losses were -$11.84 million, 12.3% more than in 2023.

Analyst Summary

According to 2 analysts, the average rating for PHAR stock is "Strong Buy." The 12-month stock price target is $38.0, which is an increase of 132.27% from the latest price.

Price Target

$38.0

(132.27% upside)

Analyst Consensus: Strong Buy